The case for universal access to HOTs is compelling on moral, economic, and strategic grounds. An estimated 10% of all global deaths are now attributable to obesity, and that burden is not evenly distributed. Lower-income populations have been subjected to decades of targeted marketing of cheap, calorie-dense foods, limited access to nutritious alternatives, higher stress loads, and less nutritional education. These are structural conditions that individuals cannot easily overcome through willpower, and a class of drugs that effectively addresses the underlying biology now exists at a manufacturing cost of under $5 per dose. The argument for restricting access to those who can afford $1,000 per month, thereby concentrating the health benefits of this disruption among those already advantaged, is difficult to defend on any ethical framework.
On the economic side, the US alone loses at least $573 billion per year to obesity, with $172 billion in direct medical costs and $401 billion in lost productivity. The return on public investment in universal HOT access would exceed the cost by a wide margin. If generic HOTs cost $10 per month and are used by all 107 million obese American adults, the total annual cost would be roughly $13 billion, against a potential economic benefit of $573 billion per year, not counting the downstream savings in healthcare, disability, criminal justice, and social services. And this is just considering obese Americans, a much larger portion of the population could benefit from optimization.
If universal HOT access meaningfully reduces the prevalence and severity of alcohol and drug addiction, and the emerging evidence suggests it would, the criminal justice and social services savings could also be enormous. As much as $110 billion of the US criminal justice budget is directly associated with drug and alcohol abuse, and reducing this would benefit not just government finances but the individuals, families, and communities most harmed by addiction.
Strategically, nations that ensure universal HOT access will have a competitive advantage in workforce productivity, healthcare costs, and long-term economic growth over those that leave access entirely to market forces. A healthier population is a more productive, more resilient, and more capable one. The WHO's 2025 addition of GLP-1 drugs to its Essential Medicines List signals the direction of emerging international consensus.
We are entering a new era of healthcare based on a categorically different kind of medicine whose purpose is not just to save us from illness, but to help us be the best version of ourselves.
The next generation of HOTs will trigger a multi-trillion-dollar global disruption, affecting dozens of industries across multiple sectors, driving a radical global improvement in health and wellness encompassing at least 1 billion people worldwide before 2040.
Optimizing well with advanced HOTs will soon become as important as eating well with nutritious foods. Nations, industries, and individuals that recognize this early and act decisively will be best positioned to capture the extraordinary benefits of this transformation.
Learn more about the HOT disruption and its implications for health, society, and the economy.
Disclaimer
The information provided in this FAQ is for general informational and educational purposes only and is not intended to constitute medical advice, diagnosis, or treatment. This content does not establish a doctor-patient relationship. The content regarding GLP-1 receptor agonists (or any other medical treatments) should not be used as a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options. Never disregard professional medical advice or delay in seeking it because of something you have read here. The authors and publishers of this FAQ and related report make no representation or warranty, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information presented. Reliance on any information provided here is solely at your own risk.